FidoCure is pioneering a revolutionary approach to treating canine cancer - bringing the power of precision medicine from human oncology to veterinary care. As the first and only service of its kind, FidoCure provides genomic testing to identify the unique genetic markers driving each dog's cancer. This information can guide individualized treatment plans and leverage cutting-edge targeted therapies and innovative medicines precisely matched to a patient's disease profile. Genomic sequencing can also provide valuable insights into diagnosis and prognosis, offering a more comprehensive underst ..read more

We are excited to share an inspiring and insightful episode of "The Veterinary Optimist" podcast, featuring our very own Christina Lopes, CEO and Co-Founder of The One Health Company. In this special episode, Christina opens up about her journey, from her father’s battle with cancer to the loss of several beloved family dogs, and how these experiences fueled her passion for revolutionizing cancer treatment for pets. Christina also delves into her background working with marginalized communities, which inspired her to focus on helping voiceless beings and ultimately led her to the veterinary ..read more

Mammary tumors are common in intact female dogs, especially middle-aged and older dogs of smaller breeds like Poodles, Chihuahuas, and Dachshunds, though some larger breeds are also at higher risk. Hormonal exposure plays a key role, with dogs spayed before their first heat cycle having only a 0.5% risk. Treatment typically involves surgical removal, which is potentially curative if the tumor is completely removed. For more invasive, advanced or metastatic cases,. Overall prognosis is quite variable depending upon key clinical features such as histopathologic subtype, tumor size, and metastas ..read more

Histiocytic sarcoma (HS) is an aggressive cancer originating from white blood cells called histiocytes that are involved in the immune system. There are three main forms, (1) localized, which presents, at least initially, at a single site such as the bones, joints, or lungs, (2) disseminated, which involves multiple organ systems at diagnosis, and (3) hemophagocytic, characterized by cancerous histiocytes destroying blood cells. HS can affect almost any organ, with certain breeds being more susceptible. The localized form is typically treated with surgical removal and chemotherapy drugs like ..read more

Melanoma is an aggressive cancer arising from pigment-producing cells, accounting for 7% of canine tumors with certain breeds at higher risk. The most common form is oral melanoma, which affects the mouth and gums, and has the potential to metastasize. Cutaneous melanomas can also occur but are less common than oral melanomas and are often benign. Treatment typically involves surgical removal followed by radiation therapy for local disease control as well as systemic therapy given the metastatic potential. Prognosis varies based on location and stage, with median survival around 17-18 months ..read more

As we round out National Cancer Research Month, we want to highlight the important work being done by FidoCure researchers in comparative oncology. At FidoCure, we’ve pioneered canine cancer research backed by real-world evidence and published our findings in 4 of the most prestigious peer-reviewed scientific journals. Many of these papers are go-to sources for groundbreaking discoveries and advancements in cancer research. Our studies, led by FidoCure’s Head of Veterinary Research, Dr. Lucas Rodrigues, DVM, MS, PhD,  have shed light on the similarities between canine and human cancers ..read more

One out of four pet dogs will be diagnosed with cancer throughout their lifetime. With nearly 6 million new canine cancer diagnoses each year, there is an urgent need for advanced treatments. Fortunately, FidoCure introduces advanced options into the cancer treatment toolbox for veterinarians and dogs, offering hope for improved outcomes ..read more

Explore the history and impact of small molecules in this fascinating discussion. FidoCure’s Chief Medical Officer, Dr. Gerry Post interviews Dr. Cheryl London about their application in canine cancer treatment. Dr. Cheryl London is a world-renowned expert in veterinary oncology and targeted cancer therapies at Tufts University. Her pioneering work began in 2000 when she collaborated with SUGEN to develop Palladia, one of the first targeted small molecule drugs approved for veterinary use, treating canine mast cell tumors driven by KIT mutations.  ..read more

Hemangiosarcoma is an aggressive, malignant tumor derived from blood vessel cells that grows rapidly, can cause severe bleeding, and has a high metastasis rate. It most commonly affects the spleen but can also occur in the heart, skin, and liver, with certain breeds like German Shepherds, Golden Retrievers, and Labradors at higher risk. Treatment typically involves surgical removal followed by chemotherapy, though targeted therapies and supplemental approaches like metronomic therapy and mushroom extracts are showing promise. Despite aggressive conventional treatment, prognosis remains guarde ..read more

Precision medicine revolutionizes cancer care by tailoring treatments to each patient's tumor, but major roadblocks remain. These top articles dive into the key challenges holding personalized oncology back and emerging solutions companies like FidoCure are exploring. You'll find insights on innovative clinical trial designs, cutting-edge technologies enabling more precise therapies, and even how studying cancer in pet dogs could accelerate new targeted drug development for both human and veterinary medicine.  ..read more